Moleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain Tumors Nov 1, 2017
Moleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin Trial Oct 18, 2017
Moleculin Engages CRO to Begin Clinical Trials of WP1220 for the Treatment of Cutaneous T-Cell Lymphoma Sep 13, 2017
Moleculin to Collaborate on Combining its WP1122 Brain Cancer Drug Candidate with Roche's Drug Avastin Sep 6, 2017
Moleculin Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference Aug 31, 2017
